Ascletis Pharma: Sell the Hype Of (Possible) Coronavirus Clinical Trial
Ascletis Pharma has been the beneficiary of the Coronavirus as media reports mention that its drug candidates that aim to treat type 1 HIV is being...
626 Views
Hong Kong Buyback Weekly: Xiaomi Is Back
Hong Kong Exchange publishes share repurchases by listed companies on a daily basis. In our weekly note, we will provide statistics on top...
399 Views
Alphamab (康宁杰瑞) Pre-IPO: Promising Readings from PHIP Updates
Alphamab obtained approval from HKSE last week and started pre-marketing for its USD 200-300m deal this week. In our previous notes, we covered the...
610 Views
Hong Kong IPO Analytics - Regular Cornerstone Investors and Track Record
At the beginning of this year, we at Aequitas Research, wrote on IPO analytics of deals across Asia-Pacific from 2016 to 2018. If you have not read...
1.2k Views
Tasly Biopharm (天士力生物) IPO: Visible Growth from Approved Drug but Lacks Blockbusters
Tasly Biopharm, a biologics R&D platform spin-off from A-share listed Tasly Pharmaceutical Group (600535 CH), is looking to raise up to USD 1...
1.2k Views